QURE N Stock Overview
Develops treatments for patients suffering from rare and other devastating diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
uniQure N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$118.63 |
| 52 Week High | US$332.49 |
| 52 Week Low | US$118.63 |
| Beta | 1.02 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -64.32% |
Recent News & Updates
Recent updates
Shareholder Returns
| QURE N | MX Biotechs | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how QURE N performed against the MX Biotechs industry.
Return vs Market: Insufficient data to determine how QURE N performed against the MX Market.
Price Volatility
| QURE N volatility | |
|---|---|
| QURE N Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: QURE N has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine QURE N's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 501 | Matt Kapusta | www.uniqure.com |
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington’s disease; AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer’s disease; and AMT-210 that is in preclinical trial to treat Parkinson’s disease. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
uniQure N.V. Fundamentals Summary
| QURE N fundamental statistics | |
|---|---|
| Market cap | Mex$5.17b |
| Earnings (TTM) | -Mex$3.91b |
| Revenue (TTM) | Mex$1.92b |
2.7x
P/S Ratio-1.3x
P/E RatioIs QURE N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| QURE N income statement (TTM) | |
|---|---|
| Revenue | US$111.90m |
| Cost of Revenue | US$222.00m |
| Gross Profit | -US$110.10m |
| Other Expenses | US$118.36m |
| Earnings | -US$228.46m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.78 |
| Gross Margin | -98.40% |
| Net Profit Margin | -204.17% |
| Debt/Equity Ratio | 37.7% |
How did QURE N perform over the long term?
See historical performance and comparison